# Poseida Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/poseida-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.poseida.com
- Total disclosed funding: $284M
- Latest round: Series D (Jun 25, 2020)
- Investors on record: 13

## About

Poseida Therapeutics, Inc., based in the US, is engaged in developing innovative genetic engineering technologies aimed at treating life-threatening cancers and genetic disorders through advanced therapeutic solutions.Founded in 2014 and headquartered in San Diego, US, Poseida Therapeutics, Inc. specializes in genetic engineering technologies. The company has undergone a significant business pivot towards advanced gene therapies. The firm achieved a milestone by raising USD 1,500.00 mn through the LP Direct funding round, with Roche Retirement Plans as a notable investor. Poseida has a total of 10 deals recorded, with its most recent deal occurring on July 9, 2020. The current leadership includes CEO Eric Ostertag, along with Kristin Yarema and Mark Gergen.Poseida Therapeutics focuses on pioneering genetic engineering technologies to address life-threatening cancers and genetic diseases. Their core product offerings include the non-viral piggyBac® DNA Delivery System, which facilitates the insertion of large genetic payloads into various genomes, and the Cas-CLOVER™ Site-Specific Gene Editing System, designed for precise genetic modifications such as deletions, insertions, and knock-ins across multiple cell types. These technologies serve as the foundation for advancing allogeneic CAR-T therapies aimed at enhancing patient outcomes in oncology and for the potential development of functional cures for rare genetic disorders. Poseida targets a diverse clientele, including research institutions, pharmaceutical companies, and biotech firms, operating primarily within North America and Europe, where the demand for advanced gene therapies continues to grow.Poseida Therapeutics generated revenue of USD 130,492,000 in the most recent year, 2022, with an EBITDA of USD -56,549,000 for the same period. The company generates revenue through strategic partnerships and collaborations with pharmaceutical firms and research institutions, focusing on the commercialization of its gene editing technologies and therapies. Their business model encompasses B2B transactions, where they license proprietary technologies to industry partners for further development and clinical application, generating income through milestone payments and royalties on future product sales.Poseida Therapeutics plans to leverage recent funding to advance its product pipeline, particularly in developing new gene therapies aimed at treating various cancers and genetic disorders. Following the IPO on July 9, 2020, where they raised USD 224 mn by selling shares on the Nasdaq, the company is expected to invest in expanding its geographical presence in both North America and Europe, targeting new markets for gene therapies. These initiatives are anticipated to enhance operational capabilities and accelerate the commercialization of their innovative genetic solutions.

## Funding rounds

- Series D, Jun 25, 2020, $110M — Adage Capital Management, Fidelity Investments, Schonfeld Strategic Advisors, Rapha Capital Management
- Series C, Apr 22, 2019, $142M — Vivo Capital, Aisling Capital, Longitude Capital, Perceptive Advisors, Boxer Capital, Malin Corporation, Novartis, Pentwater Capital Management, Rapha Capital Management
- Series B, Mar 19, 2018, $31M — Vivo Capital, Longitude Capital, Tavistock Group, Malin Corporation
- Series A, Jun 1, 2017, $1M — Rapha Capital Management

## Investors

- Rapha Capital Management (https://capitalatlas.ai/funds/rapha-capital-management) — Series A, Series C, Series D
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B, Series C
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series B, Series C
- Tavistock Group (https://capitalatlas.ai/funds/tavistock-group) — Series B
- Malin Corporation — Series B, Series C
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series C
- Novartis — Series C
- Pentwater Capital Management — Series C
- Adage Capital Management — Series D
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series D
- Schonfeld Strategic Advisors — Series D